Women's Age Lab and Women's College Research Institute, Women's College Hospital, Toronto, Ontario, Canada.
Division of General Internal Medicine and Geriatrics, Sinai Health System and the University Health Network, Toronto, Ontario, Canada.
JAMA Netw Open. 2023 Aug 1;6(8):e2327750. doi: 10.1001/jamanetworkopen.2023.27750.
The COVID-19 pandemic caused large disruptions to health care for hospitalized older adults. The incidence and management of delirium may have been affected by high rates of COVID-19 infection, staffing shortages, overwhelmed hospital capacity, and changes to visitor policies.
To measure changes in rates of delirium and related medication prescribing during the COVID-19 pandemic among hospitalized older adults.
DESIGN, SETTING, AND PARTICIPANTS: This population-based, repeated cross-sectional study used linked databases to measure rates of delirium and related medication prescriptions among adults aged 66 years or older hospitalized before and during the COVID-19 pandemic (January 1, 2017, to March 31, 2022) in Ontario, Canada.
The first 2 years of the COVID-19 pandemic (March 1, 2020, to March 31, 2022).
The main outcomes were weekly rates of delirium per 1000 admitted population and monthly rates of new antipsychotic and benzodiazepine prescriptions per 1000 discharged population. Observed rates were compared with projected rates based on modeling from 3 years before pandemic onset.
Among 2 128 411 hospitalizations of older adults over the 5-year study period (50.7% female; mean [SD] age, 78.9 [8.3] years), absolute rates of delirium increased from 35.9 per 1000 admitted population during the prepandemic period to 41.5 per 1000 admitted population throughout the pandemic. The adjusted rate ratio (ARR) of delirium during the pandemic compared with the projected rate was 1.15 (95% CI, 1.11-1.19). Monthly rates of new antipsychotic prescriptions increased from 6.9 to 8.8 per 1000 discharged population and new benzodiazepine prescriptions from 4.4 to 6.0 per 1000 discharged population and were significantly higher during the pandemic compared with projected rates (antipsychotics: ARR, 1.28; 95% CI, 1.19-1.38; benzodiazepines: ARR, 1.37; 95% CI, 1.20-1.57). Rates were highest during pandemic waves 1 (March to June 2020), 3 (March to June 2021), and 5 (December 2021 to February 2022) and remained elevated above projected levels throughout the first 2 years of the pandemic.
In this repeated cross-sectional study of hospitalized older adults, there was a temporal association between COVID-19 pandemic onset and significant increases in rates of delirium in the hospital and new antipsychotic and benzodiazepine prescriptions after hospital discharge. Rates remained elevated over 2 years. Pandemic-related changes such as visitor restrictions, staff shortages, isolation practices, and reduced staff time at the bedside may have contributed to these trends.
COVID-19 大流行导致住院老年患者的医疗服务严重中断。谵妄的发病率和管理可能受到 COVID-19 感染率高、人员短缺、医院容量不堪重负以及访客政策变化的影响。
测量 COVID-19 大流行期间住院老年患者谵妄和相关药物处方的发生率变化。
设计、地点和参与者:这项基于人群的、重复的横断面研究使用链接数据库来衡量加拿大安大略省 66 岁或以上的成年人在 COVID-19 大流行之前(2017 年 1 月 1 日至 2022 年 3 月 31 日)和期间(2020 年 3 月 1 日至 2022 年 3 月 31 日)住院期间谵妄和相关药物处方的发生率。
COVID-19 大流行的头 2 年(2020 年 3 月 1 日至 2022 年 3 月 31 日)。
主要结果是每 1000 名入院人群的每周谵妄发生率和每 1000 名出院人群的新抗精神病药和苯二氮䓬类药物的每月处方率。观察到的比率与大流行前 3 年建模预测的比率进行了比较。
在 5 年研究期间,有 2128411 名老年患者住院(50.7%为女性;平均[SD]年龄,78.9[8.3]岁),谵妄的绝对发生率从流行前时期的每 1000 名入院人群 35.9 例增加到流行期间的每 1000 名入院人群 41.5 例。与预测率相比,大流行期间谵妄的调整后率比值(ARR)为 1.15(95%CI,1.11-1.19)。新抗精神病药处方的每月比率从每 1000 名出院人群 6.9 例增加到 8.8 例,新苯二氮䓬类药物处方从每 1000 名出院人群 4.4 例增加到 6.0 例,与预测率相比,这些比率在大流行期间显著更高(抗精神病药:ARR,1.28;95%CI,1.19-1.38;苯二氮䓬类药物:ARR,1.37;95%CI,1.20-1.57)。在大流行的第 1 波(2020 年 3 月至 6 月)、第 3 波(2021 年 3 月至 6 月)和第 5 波(2021 年 12 月至 2022 年 2 月)期间,这些比率最高,并且在大流行的头 2 年期间一直高于预测水平。
在这项对住院老年患者的重复横断面研究中,COVID-19 大流行的开始与住院期间谵妄发生率的显著增加以及出院后新的抗精神病药和苯二氮䓬类药物处方之间存在时间关联。这些比率在 2 年多的时间里一直居高不下。与大流行相关的变化,如访客限制、人员短缺、隔离措施和减少工作人员在床边的时间,可能导致了这些趋势。